tbuckley/cabot-search huggingface dataset:
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
Authors: Anja Irmisch, Ximena Bonilla, Stéphane Chevrier, Kjong-Van Lehmann, Franziska Singer, Nora C. Toussaint, Cinzia Esposito, Julien Mena, Emanuela S. Milani, Ruben Casanova, Daniel J. Stekhoven, Rebekka Wegmann, Francis Jacob, Bettina Sobottka, Sandra Goetze, Jack Kuipers, Jacobo Sarabia del Castillo, Michael Prummer, Mustafa A. Tuncel, Ulrike Menzel, Andrea Jacobs, Stefanie Engler, Sujana Sivapatham, Anja L. Frei, Gabriele Gut, Joanna Ficek, Nicola Miglino, Rudolf Aebersold, Marina Bacac, Niko Beerenwinkel, Christian Beisel, Bernd Bodenmiller, Reinhard Dummer, Viola Heinzelmann-Schwarz, Viktor H. Koelzer, Markus G. Manz, Holger Moch, Lucas Pelkmans, Berend Snijder, Alexandre P.A. Theocharides, Markus Tolnay, Andreas Wicki, Bernd Wollscheid, Gunnar Rätsch, Mitchell P. Levesque, Melike Ak, Faisal S. Al-Quaddoomi, Jonas Albinus, Ilaria Alborelli, Sonali Andani, Per-Olof Attinger, Daniel Baumhoer, Beatrice Beck-Schimmer, Lara Bernasconi, Anne Bertolini, Natalia Chicherova, Maya D'Costa, Esther Danenberg, Natalie Davidson, Monica-Andreea Drăgan, Martin Erkens, Katja Eschbach, André Fedier, Pedro Ferreira, Bruno Frey, Linda Grob, Detlef Günther, Martina Haberecker, Pirmin Haeuptle, Sylvia Herter, Rene Holtackers, Tamara Huesser, Tim M. Jaeger, Katharina Jahn, Alva R. James, Philip M. Jermann, André Kahles, Abdullah Kahraman, Werner Kuebler, Christian P. Kunze, Christian Kurzeder, Sebastian Lugert, Gerd Maass, Philipp Markolin, Julian M. Metzler, Simone Muenst, Riccardo Murri, Charlotte K.Y. Ng, Stefan Nicolet, Marta Nowak, Patrick G.A. Pedrioli, Salvatore Piscuoglio, Mathilde Ritter, Christian Rommel, María L. Rosano-González, Natascha Santacroce, Ramona Schlenker, Petra C. Schwalie, Severin Schwan, Tobias Schär, Gabriela Senti, Vipin T. Sreedharan, Stefan Stark, Tinu M. Thomas, Vinko Tosevski, Marina Tusup, Audrey Van Drogen, Marcus Vetter, Tatjana Vlajnic, Sandra Weber, Walter P. Weber, Michael Weller, Fabian Wendt, Norbert Wey, Mattheus H.E. Wildschut, Shuqing Yu, Johanna Ziegler, Marc Zimmermann, Martin Zoche, Gregor Zuend
Journal: Cancer Cell (2021)
Benefit-Cost Analysis of Antimicrobial Prophylaxis in Abdominal and Vaginal Hysterectomy
Authors: Mervyn Shapiro
Journal: JAMA (1983)

We performed a benefit-cost analysis of antimicrobial prophylaxis for hysterectomy using data from a randomized, placebo-controlled clinical trial of the efficacy of three doses of cefazolin sodium. The excess cost per patient with either operative site or urinary tract infection, or febrile morbidity diagnosed during hospitalization, was $1,777 for vaginal and $716 for abdominal hysterectomy. In patients undergoing vaginal hysterectomy, prophylactic cefazolin reduced in-hospital infectious morbidity from 52% to 23% (preventive fraction, 56%), resulting in an average net benefit of $492 per patient. In abdominal hysterectomy, cefazolin decreased in-hospital morbidity from 43% to 25% (preventive fraction, 42%), resulting in an average net savings of $102 per patient. These benefits would be eroded by use of newer, more expensive cephalosporins unless they were considerably more effective than cefazolin. The benefits also would be diminished by inappropriate prolongation of the duration of prophylaxis. (<i>JAMA</i>1983;249:1290-1294)
Enhanced Late Na+Currents in Atrial Fibrillation: New Drug Target or Just an Epiphenomenon?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Ulrich Schotten, Sander Verheule, Benoit-Gilles Kerfant, Maura Greiser
Journal: Journal of the American College of Cardiology (2010)
HP0019 Physiotherapist/student for the degree of master of science
Authors: TS Søyseth, V Søyseth
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> An investigation on the effect of education or education in combination with physical training on pain experience in women with osteoporosis. <h3>Introduction</h3> Pain and fear of fracture are very common among patients with osteoporosis reducing their activity of daily living and quality of life. We have investigated the effect of education or education in combination with physical training in women with osteoporosis. <h3>Methods</h3> Women older than 60 years with osteoporosis (N = 49) were enrolled in the study. All were able to walk indoor without technical support. Bone density was assessed using a DXA-machine. All were hospitalised for five days in a hospital of rheumatology. They were casually put into two different treatment programs: Education (n = 26) Education in combination with physical train (n = 23) The education program was provided by a team of professional health workers and had a multifactorial approach to problems experienced by patients with osteoporosis. The training program was conducted by two physiotherapists. Health was assessed by SF-36 questionnaire at baseline, and then after 3 and 12 months. <h3>Results</h3> A multivariate analysis for repeated measurements showed an improvement of bodily pain score of 7.4 (95% CI 2.7–12.1) after 3 months and 9.8 (95% CI 4.2–15.4) after 1 year compared with baseline. There were no significant differences between the groups. Physical activity and social function were also statistical improved at 3 month, but the improvement did not persist for the complete follow-up period. <h3>Conclusion</h3> Participation a professional education program reduces the pain experience in women with osteoporosis, and the improvement appear to persist for at least one year. This result needs confirmation by further studies.
SAT0097 Success in osteoarthritis (oa) trial: celecoxib significantly reduces the risk of upper gastrointestinal (ugi) hospitalizations compared to diclofenac and naproxen in 13,274 randomised patients with oa
Authors: J Goldstein, G Eisen, W Bensen, N Agrawal, G Singh, K Pavelka, TA Burke, JVM Chancellor, AD Pettitt, AM Wilson, J Fort
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> NSAIDs increase the risk of serious GI hospitalizations, with studies demonstrating 5–7x increases in risk (1%?1.5% NSAID vs 0.1%-0.2% background rates). Additionally, GI-related hospitalizations impose higher cost on payers. <h3>Objectives</h3> To compare the incidence of upper GI (UGI) hospitalizations in OA patients exposed to celecoxib, a COX-2 specific inhibitor, or conventional NSAIDs (diclofenac or naproxen). <h3>Methods</h3> SUCCESS-1 in OA was a 12-week, multinational, double-blind, randomised trial in 13,274 patients, designed to reflect standard clinical practice. 6547 patients from Europe and Africa; 2756 from North America; 2889 from Latin America and 1082 from Australasia were enrolled. Patients were treated with celecoxib (200 mg/d [n = 4421] or 400 mg/d [n = 4429]) or conventional NSAIDs (naproxen 1000 mg/d [n = 914] or diclofenac 100 mg/d [n = 3510]). An independent Gastrointestinal Events Committee (GEC) categorised potential clinically significant UGI events in a blinded fashion as UGI ulcer complications (perforations, gastric outlet obstruction, bleeding) or symptomatic UGI ulcerations. UGI hospitalizations are reported as GI body system code events, investigator-determined potential UGI events, and GEC-confirmed ulcers/ulcer complications. <h3>Results</h3> <h3>Conclusion</h3> UGI hospitalisation rates were 2–4x lower, and less UGI-related healthcare resources were utilised for celecoxib- vs NSAID-treated patients. The incidence of serious clinical UGI safety endpoints was significantly lower in the celecoxib-treated patients. Sponsored by Pharmacia Corporation and Pfizer, Inc.
Optical coherence tomography(OCT)にて冠攣縮を観察し得た不安定狭心症の1例
Authors: 蒸野寿紀, 北端宏規, 柏木学, 松本啓希, 辻岡洋人, 大河内啓史, 池島英之, 有田祐, 黒井章央, 上野悟史, 片岩秀朗, 中村信男, 谷本貴志, 財田滋穂, 平田久美子, 水越正人, 田中篤, 今西敏雄, 赤阪隆史
Journal: Circulation (2008)
First Drug Approved for Rare Genetic Disorder Affecting Kidneys
Authors: Mary Chris Jaklevic
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Agminated benign vascular tumour successfully treated with trametinib
Authors: S. Greenberger, R. Stein, A. Ollech, M.E. Hartstein, O. Benyamini, M. Yalon, A. Levi, M. Lapidoth, A. Barzilai
Journal: British Journal of Dermatology (2021)

Funding sources: none. Conflicts of interest: The authors declare they have no conflicts of interest. Dear Editor, Vascular tumours are caused by the neoplastic transformation of cells constituting vascular structures. Traditionally, treatment options include surgical approaches such as resection, embolization/sclerotherapy or laser therapy, and medical treatments such as corticosteroids, beta blockers and chemotherapy. The investigation of genetic mutations underlying vascular anomalies has recently provided new insights into the genetic aetiology of these lesions,1 giving rise to personalized, targeted medical treatment that may potentially be safer and more effective. Here we describe a patient who presented with a reactive, locally disseminated vascular tumour that failed to respond to conventional treatments. Identifying a somatic mutation in the NRAS gene promoted treatment with trametinib, which resulted in rapid regression of the tumour. A 28‐year‐old healthy man presented to the Department of Dermatology at the Sheba Medical Center for evaluation of rapidly growing facial vascular lesions. Two months earlier he had experienced a small superficial burn from welding on his left nose bridge. Two weeks later, an erythemic nodule appeared in the same location. Initially, dacryocystitis was suspected. During an attempt at drainage, significant bleeding occurred and the patient was treated with electrocoagulation, followed by a course of oral amoxicillin and clavulanic acid (Figure 1a). Despite this, the lesion continued to grow in volume and expanded towards the forehead, nose and left eyelid as nodules and small papules on a faintly erythematous background. Laboratory investigations including complete blood count, chemistry, and serology for HIV, hepatitis B virus and hepatitis C virus were all within normal limits.
The impact of nutrition support in advanced gastric adenocarcinoma patients treated with chemotherapy.
Authors: Keiji Sugiyama, Kazuhiro Shiraishi, Takuya Motohashi, Shinpei Onoda, Riko Noshibori, Mariko Sato, Masaaki Shimada, Noboru Hirahsima, Masato Kataoka, Chiyoe Kitagawa
Journal: Journal of Clinical Oncology (2021)

208 Background: Numerous studies have demonstrated how malnutrition and cachexia are associated with poor survival in advanced gastric cancer (AGC). The impact of nutrition support involving multidisciplinary specialists is unclear, particularly among patients with AGC being treated with chemotherapy. This study aimed to clarify the differences in patient characteristics and survival outcomes between patients receiving nutrition support (NS) and routine care (RC). Methods: We retrospectively analyzed 212 consecutive patients with AGC at a single institution between January 2015 and June 2020. Inclusion criteria were: histologically confirmed metastatic or recurrent gastric and adenocarcinoma and gastroesophageal junction patients treated with chemotherapy, ECOG performance status (PS) 0-2, and adequate organ function. Time to treatment failure (TTF) in the entire cohort, patients with a positive Glasgow prognostic score (GPS) (graded as 1 and 2), and hypoalbuminemia (cutoff was 3.5 g/dl) were evaluated. Univariate and multivariate analyses were conducted to identify whether NS was an independent prognostic factor of time to treatment failure (TTF). Multivariate analysis included variables with p-values ≤0.1 in univariate analyses. Results: A total of 97 patients met the inclusion criteria with 67 (69%) and 30 (31%) patients classified into the RC or NS group, respectively. The median age was 71 years (range, 26-92). The median follow-up time was 8.4 months (range, 0.5-66). Patient characteristics revealed that NS was offered to patients with poorer prognostic nutritional index (PNI) (cutoff was 45, p=0.02), GPS positivity (p=0.01), and high neutrophil-lymphocyte ratio (NLR) (cutoff was 3, p=0.01). In the entire cohort, TTF in the RC and NS groups was 4.3 and 5.3 months (p=0.15), respectively. Among the patients with GPS positivity (graded as 1 and 2) and hypoalbuminemia, TTF in the RC and NS group were 2.3 and 5.0 months (p=0.05), and 2.3 and 5.3 months (p=0.02), respectively (Table). Variables with p-values ≤0.1 in univariate analyses for TTF were PS, NS, and prior gastrectomy. As per multivariate analyses, PS and NS were significant positive prognostic factors for TTF. Conclusions: NS was provided to patients with unfavorable clinical features. Among the AGC patients treated with chemotherapy, having GPS positivity or hypoalbuminemia seems to be a good indication for NS. [Table: see text]
Myotonic dystrophy kinase‐related <scp>CDC42</scp>‐binding kinase α, a new transferrin receptor type 2‐binding partner, is a regulator of erythropoiesis
Authors: Cyrielle Richard, Sophie Viret, Lilia Cantero Aguilar, Carine Lefevre, Marjorie Leduc, El Hassan Faouzi, Nabih Azar, Catherine Lavazec, Patrick Mayeux, Frédérique Verdier
Journal: American Journal of Hematology (2021)

Efficient erythropoiesis relies on the expression of the transferrin receptor type 2 (TFR2). In erythroid precursors, TFR2 facilitates the export of the erythropoietin receptor (EPOR) to cell surface, which ensures the survival and proliferation of erythroblasts. Although TFR2 has a crucial role in erythropoiesis regulation, its mechanism of action remains to be clarified. To understand its role better, we aimed at identifying its protein partners by mass-spectrometry after immunoprecipitation in erythroid cells. Here we report the kinase MRCKα (myotonic dystrophy kinase-related CDC42-binding kinase α) as a new partner of both TFR2 and EPOR in erythroblasts. We show that MRCKα is co-expressed with TFR2, and TFR1 during terminal differentiation and regulates the internalization of the two types of transferrin receptors. The knockdown of MRCKα by shRNA in human primary erythroblasts leads to a decreased cell surface expression of both TFR1 and TFR2, an increased cell-surface expression of EPOR, and a delayed differentiation. Additionally, knockout of Mrckα in the murine MEDEP cells also leads to a striking delay in erythropoiesis, showcasing the importance of this kinase in both species. Our data highlight the importance of MRCKα in the regulation of erythropoiesis.
Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.
Authors: Keisho Chin, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Journal: Journal of Clinical Oncology (2021)

204 Background: Previous results from the ATTRACTION-3 phase 3 trial demonstrated a significant improvement in overall survival and a favorable safety profile compared with taxane chemotherapy (CT) in previously-treated ESCC patients. To our knowledge, no long-term efficacy and safety data of this immune checkpoint inhibitor has been reported in ESCC. Herein, we report the three-year survival data of Nivo in ESCC. Methods: In ATTRACTION-3, 419 patients with unresectable advanced or recurrent ESCC refractory or intolerant to 1 prior fluoropyrimidine/platinum-based CT were randomized in a 1:1 ratio to receive Nivo (N = 210) or the investigator’s choice of CT (paclitaxel or docetaxel) (N = 209) until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS). A subgroup analysis of OS according to the best overall response (BOR) was performed. The onset of treatment-related adverse events of special interest over time in the Nivo arm was also evaluated. Results: As of data cut-off on 25 May 2020, 3 years after the last patient was enrolled, the median OS (mOS) was 10.91 months with Nivo versus 8.51 months with CT [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.64-0.97]. The OS rates of patients with Nivo and CT were 20.2 % and 13.5 % at 24 months, and 15.3% and 8.7% at 36 months, respectively. In the subgroup analysis of OS by BOR, mOS in CR/PR patients were 19.91 and 15.41 months (HR 0.84, 95%CI 0.46-1.54) and that in SD patients were 17.38 and 9.36 months (HR 0.45, 95%CI 0.26-0.78) in the Nivo and CT arm, respectively. Furthermore, mOS in PD patients were 10.91 and 6.18 months (HR 0.56, 95%CI 0.33-0.95) in the Nivo and CT arm, respectively. No new safety signals were detected during the three-year follow-up. Time to onset of the event of special interest was within the range of events previously observed in other indications. Conclusions: At three-year follow up, Nivo continued to show improved OS over CT in pretreated patients with advanced ESCC patients. Nivo showed a longer mOS than CT regardless of BOR. During the three-year follow-up, no new safety signals were observed. Clinical trial information: NCT02569242.
Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study
Authors: Neel S. Bhatt, Malek J. Baassiri, Wei Liu, Nickhill Bhakta, Wassim Chemaitilly, Matthew J. Ehrhardt, Hiroto Inaba, Kevin Krull, Kirsten K. Ness, Jeffrey E. Rubnitz, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson, Daniel A. Mulrooney
Journal: Leukemia (2021)
Selecting the optimal neoadjuvant treatment approach based on the risk of an involved surgical margin in locally advanced adenocarcinoma of the esophagus and esophagogastric junction.
Authors: Tim Spencer, Jonathan Helbrow, Eleanor Pilsworth, Stephen Falk, Helen Winter, Thomas Bird
Journal: Journal of Clinical Oncology (2021)

198 Background: Optimal neoadjuvant (NA) treatment for adenocarcinoma of the esophagus and esophagogastric junction is unknown. This study aims to evaluate an approach of offering NA chemoradiotherapy (CRT) to T3/T4 tumours with a threatened circumferential resection margin (CRM) on staging imaging (computerized tomography/endoscopic ultrasound/positron emission tomography) and NA chemotherapy (CT) to T3/T4 tumours with a non-threatened CRM. Methods: Cases with clinically staged T3/T4 tumours who underwent a radical esophagectomy at a single tertiary referral centre between 2013 and 2019 were retrospectively reviewed. NA CRT was given as 41.4Gqy in 23 fractions with weekly carboplatin/paclitaxel and NA CT was given as a platinum based combination. Survival outcomes are described using the Kaplan-Meier method and calculated from NA treatment start. Results: 81 patients were identified - 18 (22%) received CRT and 63 (78%) received CT. More cases had Stage IVA disease in the CRT group (28% vs. 8%). CT consisted of a platinum/fluoropyrimidine doublet (43%), triplet with epirubicin (51%) or FLOT (6%). Median follow up was 68 months. Median length of post-operative stay (11 days for both) and rate of death within 90 days of surgery (6% vs. 3%) were similar. Rates of R0 resection (100% vs. 67%) and tumour regression grade 1/2 (55% vs. 14%) favoured CRT. There was no difference in overall survival (HR 0.92 (95%CI: 0.45-1.87), p=0.81). Estimated 3 year relapse-free survival was 39% (95%CI: 14-64) for CRT and 45% (95%CI: 33-58) for CT. Location of first relapse was local, distant or both in 0%, 75% and 25% for CRT and 6%, 50% and 44% for CT. In the CT group, overall survival was inferior for patients with an R1 resection (HR: 6.30 (95%CI 3–14), p&lt;0.001). Conclusions: Neoadjuvant chemoradiotherapy for CRM-threatened cases of locally advanced adenocarcinoma of the esophagus and esophagogastric junction resulted in a very low rate of R1 resection and similar survival outcomes to non-CRM-threatened cases treated with neoadjuvant chemotherapy. Tailoring the neoadjuvant approach based on risk to CRM involvement appears feasible and warrants further investigation. [Table: see text]
FRI0241 Lumbar lordosis in acute and chronic low back pain patients
Authors: D Evcik, A Yücel
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Objectives</h3> Low back pain (LBP) is a major health problem affecting the adult population. Postural changes are one of the risk factor in some cases. Abnormal posture makes a strain on ligaments and muscules that indirectly affects the curvature of lumbal spine. The purpose of this study was to investigate the relationship between the angles of lumbar spine and spinal mobility in acute and chronic LBP patients. <h3>Methods</h3> Fifty patients (25 female, 25 male) with chronic Low Back Pain (CLBP) and fifty patients (30 female, 20 male) with acute low back pain (ALBP) were included the study. Both groups were subjected to lumbosacral radiography in lateral position while they were standing. Measurements were made directly from the radiographs. Patients were assessed by parameters such as spinal mobility, sacral inclination angle, lumbosacral angle and sacral horizontal angle. Spinal mobility included lumbar spinal flexion and extension and measured by double inclinometer method. <h3>Results</h3> There were no statistical differences between age and gender in both groups (p &gt; 0.05). The value of the SIA was significantly increased in CLBP patients compared to ALBP group. It was also correlated with lumbar extension in CLBP patients (p &lt; 0.005). There was no statistical difference in LSA between ALBP and CLBP groups (p &gt; 0.05). There was also no observable difference between two groups and no correlation with lomber flexion and extension for men and women (p &gt; 0.05). <h3>Conclusion</h3> The weakness of these muscles may cause a forward posture and an increase in lumbar lordosis. Additional researches should be helpful to confirm the relationship between the angles of lumbar spine and low back pain. <h3>References</h3> Amonoo-Kuofi HS. Changes in the lumbosacral angle, sacral inclination and the curvature of the lumbar spine during aging. Acta Anat. 1992;145:373–7 Youdas JW, Garrett TR, Harmsen S, <i>et al</i>. Lumbar lordosis and pelvic inclination of asymptomatic adults. Phys Ther. 1996;76:1066–81 Youdas JW, Garrett TR, Egan KS, Therneau TM. Lumbar lordosis and pelvic inclination in adults with chronic low back pain. Phys Ther. 2000;80:261–75 Hansson T, Bigos S, Beecher P, Wortley M. The lumbar lordosis in acute and chronic low-back pain. Spine 1985;10(2):154–5